freeze-thaw cycle raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material may be hygroscopic |
| Solubility class | Soluble in water, DMSO and DMF | Dilution into aqueous buffer can cause precipitation |
| Storage of solid | Minus 20 degrees C, desiccated, dark | Aliquot to limit repeated opening of the vial |
| Storage of solution | Minus 20 to minus 80 degrees C, aliquoted | Avoid repeated freeze-thaw cycles |
| Identity method | Reversed-phase HPLC with mass spectrometry | Retention time and mass are checked together |
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
AN has the highest mortality rate of any psychological disorder. The mortality rate is 11 to 12 times greater than in the general population, and the suicide risk is 56 times higher. Half of women with AN achieve a full recovery, while an additional 20–30% may partially recover. Not all people with anorexia recover completely: about 20% develop anorexia nervosa as a chronic disorder. If anorexia nervosa is not treated, serious complications such as heart conditions and kidney failure can arise and eventually lead to death. The average number of years from onset to remission of AN is seven for women and three for men. After ten to fifteen years, 70% of people no longer meet the diagnostic criteria, but many still continue to have eating-related problems. People who have autism recover more slowly, probably due to autism's effects on thinking patterns, such as reduced cognitive flexibility. Alexithymia (inability to identify and describe one's own emotions) influences treatment outcome. Recovery is also viewed on a spectrum rather than black and white. According to the Morgan-Russell criteria, individuals can have a good, intermediate, or poor outcome. Even when a person is classified as having a "good" outcome, weight only has to be within 15% of average, and normal menstruation must be present in females. The good outcome also excludes psychological health. Recovery for people with anorexia nervosa is undeniably positive, but recovery does not mean a return to normal.
Class AA ("Double-A") was established in 1912, as the new highest classification of Minor League Baseball. Previously, Class A had been the highest level, predating the establishment of the National Association of Professional Baseball Leagues—the formal name of Minor League Baseball—in 1901. Entering the 1912 season, three leagues were designated as Class AA:
==== 1.D Non-ribosomally synthesized channels ==== 1.D.1 The Gramicidin A Channel Family 1.D.2 The Channel-forming Syringomycin Family 1.D.3 The Channel-Forming Syringopeptin Family 1.D.4 The Tolaasin Channel-forming Family 1.D.5 The Alamethicin or Peptaibol Antibiotic Channel-forming Family 1.D.6 The Complexed Poly 3-Hydroxybutyrate Ca2+ Channel (cPHB-CC) Family 1.D.7 The Beticolin Family 1.D.8 The Saponin Family 1.D.9 The Polyglutamine Ion Channel (PG-IC) Family 1.D.10 The Ceramide-forming Channel Family 1.D.11 The Surfactin Family 1.D.12 The Beauvericin (Beauvericin) Family 1.D.13 DNA-delivery Amphipathic Peptide Antibiotics (DAPA) 1.D.14 The Synthetic Leu/Ser Amphipathic Channel-forming Peptide (l/S-SCP) Family 1.D.15 The Daptomycin (Daptomycin) Family 1.D.16 The Synthetic Amphipathic Pore-forming Heptapeptide (SAPH) Family 1.D.17 Combinatorially-designed, Pore-forming, β-sheet Peptide Family 1.D.18 The Pore-forming Guanosine-Bile Acid Conjugate Family 1.D.19 Ca2+ Channel-forming Drug, Digitoxin Family 1.D.20 The Pore-forming Polyene Macrolide Antibiotic/fungal Agent (PMAA) Family 1.D.21 The Lipid Nanopore (LipNP) Family 1.D.22 The Proton-Translocating Carotenoid Pigment, Zeaxanthin Family 1.D.23 Phenylene Ethynylene Pore-forming Antimicrobial (PEPA) Family 1.D.24 The Marine Sponge Polytheonamide B (pTB) Family 1.D.25 The Arylamine Foldamer (AAF) Family 1.D.26 The Dihydrodehydrodiconiferyl alcohol 9'-O-β-D-glucoside (DDDC9G) Family 1.D.27 The Thiourea isosteres Family 1.D.28 The Lipopeptaibol Family 1.D.29 The Macrocyclic Oligocholate Family 1.D.30 The Artificial Hydrazide-appended pillar[5]arene Channels (HAPA-C) Family 1.D.31 The Amphotericin B Family 1.D.32 The Pore-forming Novicidin Family 1.D.33 The Channel-forming Polytheonamide B Family 1.D.34 The Channel-forming Oligoester Bolaamphiphiles 1.D.35 The Pore-forming cyclic Lipodepsipeptide Family 1.D.36 The Oligobornene Ion Channel Family 1.D.37 The Hibicuslide C Family 1.D.38 The Cyclic Peptide Nanotube (cPepNT) Family 1.D.39 The Light-controlled Azobenzene-based Amphiphilic Molecular Ion Channel (AAM-IC) Family 1.D.40 The Protein-induced Lipid Toroidal Pore Family 1.D.41 The Sprotetonate-type Ionophore (Spirohexanolide) Family 1.D.42 The Phe-Arg Tripeptide-Pillar[5]Arene Channel (TPPA-C) Family 1.D.43 The Triazole-tailored Guanosine Dinucleoside Channel (TT-GDN-C) Family 1.D.44 The Synthetic Ion Channel with Redox-active Ferrocene (ICRF) Family 1.D.45 The Sonoporation and Electroporation Membrane Pore (SEMP) Family 1.D.46 The DNA Nanopore (DnaNP) Family 1.D.47 The Pore-forming Synthetic Cyclic Peptide (PSCP) Family 1.D.48 The Pore-forming Syringomycin E Family 1.D.49 The Transmembrane Carotenoid Radical Channel (CRC) Family 1.D.50 The Amphiphilic bis-Catechol Anion Transporter (AC-AT) Family 1.D.51 The Protein Nanopore (ProNP) Family 1.D.52 The Aromatic Oligoamide Macrocycle Nanopore (OmnNP) Family 1.D.53 The alpha, gamma-Peptide Nanotube (a,gPepNT) Family 1.D.54 The potassium-selective Hexyl-Benzoureido-15-Crown-5-Ether Ion Channel (HBEC) Family 1.D.55 The Porphyrin-based Nanopore (PorNP) Family 1.D.56 The Alpha-Aminoisobutyrate (Aib) Oligomeric Nanopore (AibNP) Family 1.D.57 The Lipid Electro-Pore (LEP) Family 1.D.58 The Anion Transporting Prodigiosene (Prodigiosene) Family 1.D.59 The Anion Transporting Perenosin (Perenosin) Family 1.D.60 The Alpha,Gamma-Cyclic Peptide (AGCP) Family 1.D.61 The Anionophoric 2,6-Bis(Benzimidazol-2-yl)Pyridine (ABBP) Family 1.D.62 The Bis-Triazolyl DiGuanosine Derivative Channel-forming (TDG) Family 1.D.63 The Peptide-based Nanopore (PepNP) Family 1.D.64 The Carbon Nanotube (CarNT) Family 1.D.65 The Pore-forming Amphidinol (Amphidinol) Family 1.D.66 The Helical Macromolecule Nanopore (HmmNP) Family 1.D.67 The Crown Ether-modified Helical Peptide Ion Channel (CEHP) Family 1.D.68 The Pore-forming Pleuronic Block Polymer (PPBP) Family 1.D.69 The Conical Nanopore (ConNP) Family 1.D.70 The Metallic (Au/Ag/Pt/graphene) Nanopore (MetNP) Family 1.D.71 The Synthetic TP359 Peptide (TP359) Family 1.D.72 The Chloride Carrier Triazine-based Tripodal Receptor (CCTTR) Family 1.D.73 The Mesoporous Silica Nanopore (SilNP) Family 1.D.74 The Stimulus-responsive Synthetic Rigid p-Octiphenyl Stave Pore (SSROP) Family
PeptideAtlas is a proteomics data resource that gathers tandem mass spectrometry datasets from around the world, reprocesses them with the Trans-Proteomic Pipeline, and makes the combined result freely available to the community. Peptide Atlas is one of the founding members of the ProteomeXchange Consortium.
Sources: en.wikipedia.org
== Endolithic fungi found in the eggs of Cretaceous dinosaurs == Evidence of endolithic fungi were discovered within dinosaur eggshell found in central China. They were characterized as being “needle-like, ribbon-like, and silk-like.". Fungus is seldom fossilized and even when it is preserved it can be difficult to distinguish endolithic hyphae from endolithic cyanobacteria and algae. Endolithic microbes can, however, be distinguished based on their distribution, ecology, and morphology. According to a 2008 study, the endolithic fungi that formed on the eggshells would have resulted in the abnormal incubation of the eggs and may have killed the embryos in infected eggs of these dinosaurs. It may also have led to the preservation of dinosaur eggs, including some that contained embryos.
Duchenne muscular dystrophy causes progressive muscle weakness due to muscle fiber disarray, death, and replacement with connective tissue or fat. The voluntary muscles are affected first, especially those of the hips, pelvic area, thighs, calves. It eventually progresses to the shoulders and neck, followed by arms, respiratory muscles, and other areas. Fatigue is common. Signs usually appear before age five, and may even be observed when a boy takes his first steps. There is general difficulty with motor skills, which can result in an awkward manner of walking, stepping, or running. They tend to walk on their toes, in part due to shortening of the Achilles tendon, and because it compensates for knee extensor weakness. Falls can be frequent. It becomes increasingly difficult for the boy to walk. The ability to walk usually disintegrates completely before age 13. Most men affected with Duchenne muscular dystrophy become essentially "paralyzed from the neck down" by the age of 21. Cardiomyopathy, particularly dilated cardiomyopathy, is common, seen in half of 18-year-olds. The development of congestive heart failure or arrhythmia (irregular heartbeat) is only occasional. In late stages of the disease, respiratory impairment and swallowing impairment can occur, which can result in pneumonia.
==== 800–899 ==== South Eastern Combined Fire Area Administration (Amendment) (No. 2) Scheme Order 1993 (S.I. 1993/800) Greater London and Kent (County Boundaries) (Variation) Order 1993 (S.I. 1993/805) Pensions Increase (Civil Service Early Retirement Pension Scheme 1992) Regulations 1993 (S.I. 1993/806) Injuries in War (Shore Employments) Compensation (Amendment) Scheme 1992 S.I. 1993/807) Devon Ambulance Service National Health Service Trust Dissolution Order 1993 (S.I. 1993/809) Cornwall Community Healthcare National Health Service Trust Dissolution Order 1993 (S.I. 1993/810) Walsgrave Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/811) Walsgrave Hospital National Health Service Trust Dissolution Order 1993 (S.I. 1993/812) Cornwall Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/813) Westcountry Ambulance Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/814) Reconstitution of the Romney Marsh Levels Internal Drainage Board Order 1993 (S.I. 1993/815) Reconstitution of the Finningley Internal Drainage Board Order 1993 (S.I. 1993/816) Reconstitution of the River Stour (Kent) Internal Drainage Board S.I. 1993/817) Civil Legal Aid (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/818) Advice and Assistance (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/819) Harefield Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/820) Social Security (Contributions) Amendment (No. 5) Regulations 1993 (S.I.
Sources: en.wikipedia.org
The Reconquista was a series of military and cultural campaigns by northern Iberian Christian polities against al-Andalus. The death of the Umayyad emir Abd ar-Rahman II in 852 brought an end to Umayyad efforts to extend authority northward. The discovery in the 830s of a tomb believed to be that of James the Great gave the Christians a powerful patron, and the elevation of Alfonso III of Asturias in the 860s ended a period of uncertain leadership, thereby providing the command required to channel this energy into a wave of expansionism southward. In 868, the region between the Minho and Douro rivers was secured from the Moors by Christian forces under Vímara Peres and constituted as the County of Portugal under him. The first county of Portugal lasted until 1071. In 1096, Alfonso VI of León refounded the county and bestowed it on Henry of Burgundy, who married Alfonso's illegitimate daughter, Teresa of León.
==== Suprageneric subdivisions ==== Due to the diversity of the originally broadly defined Liliaceae s.l., many attempts have been made to form suprageneric classifications, e.g. subfamilies and tribes. Classifications published since the use of molecular methods in phylogenetics have taken a narrower view of the Liliaceae (Liliaceae s.s.). The Angiosperm Phylogeny Website (APweb) recognizes three subfamilies, one of which is divided into two tribes.
== Diagnosis == A genetic test is available for Type 1 PSSM. This test requires a blood or hair sample, and is less-invasive than muscle biopsy. However, it may be less useful for breeds that are more commonly affected by Type 2 PSSM, such as light horse breeds. Often a muscle biopsy is recommended for horses displaying clinical signs of PSSM but who have negative results for GSY1 mutation. A muscle biopsy may be taken from the semimembranosis or semitendinosis (hamstring) muscles. The biopsy is stained for glycogen, and the intensity of stain uptake in the muscle, as well as the presence of any inclusions, helps to determine the diagnosis of PSSM. This test is the only method for diagnosing Type 2 PSSM. Horses with Type 1 PSSM will usually have between 1.5 and 2 times the normal levels of glycogen in their skeletal muscle. While abnormalities indicating muscle damage can be seen on histologic sections of muscle as young as 1 month of age, abnormal polysaccharide accumulation may take up to 3 years to develop.
Sources: en.wikipedia.org
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.
Peptides are commonly isolated as acetate or trifluoroacetate salts, and the counterion contributes to total mass. Two vials with identical peptide content can therefore differ in weight and in measured response. Residual trifluoroacetate is also relevant in cell-based work because it can influence membrane behaviour.
Degradation products are often closely related to the parent molecule, making them hard to resolve with a single method. Counterion variability adds a further source of scatter between laboratories. Because no pharmacopoeial monograph exists for melanotan-2, groups rely on method-specific validation rather than a shared reference standard.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.